Qiagen NV
NYSE:QGEN

Watchlist Manager
Qiagen NV Logo
Qiagen NV
NYSE:QGEN
Watchlist
Price: 42.78 USD 1.06% Market Closed
Market Cap: 9.5B USD
Have any thoughts about
Qiagen NV?
Write Note

Qiagen NV
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Qiagen NV
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Qiagen NV
NYSE:QGEN
Revenue
$2B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
4%
No Stocks Found

Qiagen NV
Revenue Breakdown

Breakdown by Geography
Qiagen NV

Total Revenue: 2B USD
100%
Total Americas: 1B USD
51.9%
Europe, Middle East And Africa: 624.6m USD
31.8%
Asia Pacific, Japan And Rest Of World: 320.7m USD
16.3%
Netherlands: 20.3m USD
1%
Show More
Show Less

Breakdown by Segments
Qiagen NV

Total Revenue: 2B USD
100%
Diagnostic Solutions: 697.6m USD
35.5%
Sample Technologies: 663m USD
33.7%
Pcr / Nucleic Acid Amplification: 300.2m USD
15.3%
Genomics / Ngs: 238.9m USD
12.2%
Other: 65.6m USD
3.3%
Show More
Show Less

Qiagen NV
Glance View

Market Cap
9.5B USD
Industry
Life Sciences Tools & Services

Qiagen NV is a leading global provider of sample and assay technologies that empower researchers and healthcare professionals in their quest for answers in genomics and molecular biology. Founded in 1984 and headquartered in Hilden, Germany, the company has established a formidable presence in the biotechnology sector, offering innovative solutions that facilitate the detection of diseases, genetic research, and drug development. Qiagen’s diverse portfolio spans from nucleic acid extraction kits to molecular diagnostic tests, catering to both academic research institutions and clinical settings. This extensive product range not only supports the growing demand for precision medicine but also aligns with global health trends emphasizing personalized treatments based on genetic insights. For investors, Qiagen presents an appealing opportunity as it operates in a lucrative market characterized by robust growth prospects. The company has consistently demonstrated its ability to adapt to changing healthcare landscapes, evidenced by its strategic focus on expanding offerings in molecular diagnostics and companion diagnostics, which underpin the future of targeted therapies. Additionally, Qiagen's commitment to innovation is underscored by significant investments in research and development, positioning it well to capitalize on advances in the rapidly evolving life sciences market. With a strong financial track record and a commitment to enhancing shareholder value through strategic partnerships and acquisitions, Qiagen is not just a participant in the biotech ecosystem; it is a leader steering the course for future advancements in health and research.

QGEN Intrinsic Value
40.9 USD
Overvaluation 4%
Intrinsic Value
Price

See Also

What is Qiagen NV's Revenue?
Revenue
2B USD

Based on the financial report for Sep 30, 2024, Qiagen NV's Revenue amounts to 2B USD.

What is Qiagen NV's Revenue growth rate?
Revenue CAGR 10Y
4%

Over the last year, the Revenue growth was 1%. The average annual Revenue growth rates for Qiagen NV have been -4% over the past three years , 5% over the past five years , and 4% over the past ten years .

Back to Top